Testosterone Undecanoate Injectable (Aveed / Nebido)

Quick Reference Card

Overview / What Is Testosterone Undecanoate Injectable?

The Basics

Testosterone undecanoate injectable is a long-acting form of testosterone replacement therapy that stands out from other injectable options because of how rarely you need to receive it. While testosterone cypionate and enanthate typically require injections every one to two weeks, testosterone undecanoate is administered roughly every ten to fourteen weeks, meaning just four to six injections per year.

The medication is sold under the brand name Aveed in the United States and Nebido in Europe, the United Kingdom, Australia, and many other countries. Both products contain the same active ingredient, testosterone undecanoate, dissolved in castor oil. The key difference between them is the dose and some regulatory requirements. In the US, Aveed comes with a boxed warning and a restricted distribution program (called REMS) because of a small but real risk of a reaction called pulmonary oil microembolism, which can cause coughing, chest tightness, and dizziness shortly after injection. This means every Aveed injection must be given in a certified healthcare setting, and you need to stay for 30 minutes of observation afterward.

For men who dislike frequent self-injections or find it difficult to maintain a consistent injection schedule, testosterone undecanoate offers a practical alternative. It works the same way as other testosterone formulations once the ester is cleaved and free testosterone is released into the bloodstream. The tradeoff is a larger injection volume, a longer needle, higher cost (particularly in the US), and the need for office-based administration.

The Science

Testosterone undecanoate (TU) is a long-chain fatty acid ester of testosterone, characterized by an 11-carbon undecanoic acid side chain attached at the 17-beta hydroxyl position of the testosterone molecule. This extended ester chain confers high lipophilicity, resulting in very slow release from the intramuscular depot and an elimination half-life of approximately 33.9 days (compared to approximately 8 days for testosterone cypionate and 4.5 days for testosterone enanthate) [1][2].

Injectable TU was first developed for clinical use in the early 2000s and became available in Europe as Nebido (Bayer) in 2003. The US formulation, Aveed (Endo Pharmaceuticals), received FDA approval in March 2014 after a protracted approval process that included additional safety requirements due to the risk of pulmonary oil microembolism (POME) reactions observed in clinical trials [3]. TU remains the only long-acting injectable testosterone formulation approved by the FDA, requiring only five to six injections per year at steady state.

Medical / Chemical Identity

Brand Names by Country

Ester Chemistry

Testosterone undecanoate is the longest commercially available testosterone ester. The 11-carbon fatty acid chain (undecanoic acid) creates a highly lipophilic prodrug that, when injected intramuscularly in castor oil, forms a depot from which the compound is released very slowly. Ester hydrolysis by non-specific tissue and plasma esterases cleaves the undecanoate chain at the C-17 position, liberating free testosterone into systemic circulation.

Comparative ester chain lengths:

Mechanism of Action

The Basics

Testosterone undecanoate works in the same fundamental way as every other form of testosterone replacement. Once injected into muscle tissue, the medication sits as an oily depot. Over the following weeks, your body's enzymes gradually strip away the undecanoate ester (a chemical "tail"), releasing free testosterone into your bloodstream. From that point on, the testosterone behaves identically to what your body produces naturally.

Free testosterone travels through the blood and enters cells throughout your body, where it binds to androgen receptors. This binding triggers changes in gene expression that support muscle protein synthesis, bone mineral maintenance, red blood cell production, sexual function, mood regulation, and cognitive processes. Some testosterone also gets converted into two important metabolites: dihydrotestosterone (DHT), which is more potent and drives effects on hair, skin, and prostate tissue; and estradiol, a form of estrogen that men need in small amounts for bone health, cardiovascular protection, and brain function.

The key difference with TU compared to shorter-acting esters is timing. Because the undecanoate ester is longer, the release is slower and more gradual, which can provide more stable blood levels over a longer period, though peak-to-trough variation still occurs across the 10-14 week dosing interval.

The Science

Following intramuscular injection of testosterone undecanoate in castor oil vehicle, the compound is deposited as a lipophilic depot in muscle tissue. First-order absorption kinetics govern the slow release of TU into the systemic circulation, where non-specific esterases in plasma and peripheral tissues hydrolyze the ester bond at the C-17 position, liberating free testosterone [1][4].

Free testosterone exerts its biological effects through binding to the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The classical genomic pathway involves ligand-AR complex formation, receptor dimerization, nuclear translocation, and binding to androgen response elements (AREs) in target gene promoters, modulating transcription over hours to days. Non-genomic signaling through membrane-associated androgen receptors activates rapid second messenger cascades (MAPK/ERK, PI3K/Akt) within seconds to minutes [5].

Testosterone undergoes two primary metabolic conversions:

1. 5-alpha reductase (types I and II) irreversibly converts testosterone to 5-alpha-dihydrotestosterone (DHT), which has approximately 2-3 times greater AR binding affinity and mediates androgenic effects in skin, hair follicles, and prostate tissue [5].
2. Aromatase (CYP19A1), expressed predominantly in adipose tissue, brain, and bone, converts testosterone to 17-beta-estradiol (E2). Estradiol is essential for bone mineral density maintenance, epiphyseal plate regulation, negative feedback on GnRH/LH secretion, and neuroprotective functions [5].

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, reducing GnRH pulse frequency and amplitude, which in turn decreases LH and FSH secretion. This suppression leads to reduced intratesticular testosterone concentrations and impaired spermatogenesis [6].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

When testosterone undecanoate is injected into the gluteal muscle, the castor oil solution forms a reservoir that slowly releases the drug over many weeks. The undecanoate ester is the longest available testosterone ester, which is why TU can maintain testosterone levels for so much longer than cypionate or enanthate.

After injection, testosterone levels typically rise to a peak within one to two weeks, then gradually decline over the following weeks. With the Aveed protocol (injections at weeks 0, 4, and then every 10 weeks), most patients maintain trough testosterone levels in the normal male range (300-1000 ng/dL) before each subsequent injection, though individual responses vary. Some men find that their levels dip below the target range by weeks 8-9, which is why some providers adjust the injection interval.

The loading phase matters with this formulation. The first two injections are spaced just four weeks apart (Aveed) or six weeks apart (Nebido) to build up a baseline depot. After that, the longer interval begins. It typically takes two to three injection cycles before levels fully stabilize.

The Science

Absorption: Following IM injection of TU in castor oil, slow first-order absorption from the muscle depot governs systemic drug delivery. Peak serum testosterone concentrations (Cmax) of approximately 600-900 ng/dL are typically achieved within 7-14 days post-injection. The rate of absorption is influenced by injection volume, injection site vascularity, and physical activity level [1][2].

Distribution: Circulating testosterone is approximately 44% bound to sex hormone-binding globulin (SHBG), 54% bound to albumin and other proteins, and approximately 2% unbound (free testosterone). The free and albumin-bound fractions (collectively "bioavailable testosterone") are considered the biologically active pool [1].

Metabolism: Testosterone is metabolized via 5-alpha reductase to dihydrotestosterone (DHT) and via aromatase (CYP19A1) to estradiol (E2). Phase II metabolism involves glucuronidation and sulfation. In the 84-week phase III clinical trial, DHT:T and E2:T ratios remained within the adult male reference range at all measured time points once steady state was attained [2].

Elimination: The terminal elimination half-life of testosterone undecanoate in castor oil vehicle is approximately 33.9 ± 4.9 days after the fourth injection. Approximately 90% of a testosterone dose is excreted in urine as glucuronic and sulfuric acid conjugates; about 6% is excreted in feces [1].

Pharmacokinetic Comparison Table:

Understanding how your testosterone ester is absorbed and metabolized is one thing. Tracking your actual injection protocol, including doses, timing, and injection sites, gives you the data to have more productive conversations with your prescriber. Doserly lets you log every injection with ester-specific detail, building a clear record of your testosterone protocol over time.

Whether you're on cypionate twice weekly, enanthate every 3.5 days, or undecanoate every ten weeks, the app tracks your schedule and flags when your next dose is due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

The clinical evidence for injectable testosterone undecanoate comes from several key studies. The pivotal FDA approval trial followed 130 hypogonadal men for 84 weeks, showing that the medication maintained testosterone levels within the normal range for the vast majority of patients. Long-term studies spanning more than eight years have demonstrated a consistent safety profile with sustained benefits in body composition, metabolic health, and sexual function.

The TRAVERSE trial, the largest randomized controlled trial on testosterone therapy and cardiovascular safety, used testosterone gel rather than injectable TU specifically. However, its findings are considered relevant to all testosterone formulations because the cardiovascular effects relate to testosterone itself rather than the delivery method. TRAVERSE found that testosterone therapy did not increase the rate of major cardiovascular events compared to placebo in men with cardiovascular risk factors.

One area where TU has unique safety data is the risk of pulmonary oil microembolism (POME), a reaction specific to oil-based intramuscular injections of large volume. This risk led to the boxed warning and REMS requirement for Aveed in the US.

The Science

Pivotal Phase III Trial (Wang et al., 2010): This 84-week, open-label, multicenter trial enrolled 130 hypogonadal men (serum total T <300 ng/dL) who received 750 mg TU IM at weeks 0, 4, and then every 10 weeks for 9 total injections. Primary endpoint: 94% of patients maintained average serum T within the normal range (300-1000 ng/dL) at all measured time points. Serum free T, DHT, and E2 remained within reference ranges at steady state [2].

Long-term Safety (Saad et al., 2013): Registry data on patients treated with injectable TU for more than 8 years demonstrated sustained improvements in body composition (fat mass reduction, lean mass increase), glycemic control (HbA1c reduction), and lipid profiles. No increased risk of prostate cancer or cardiovascular disease was observed over the observation period [7].

TRAVERSE Trial (Lincoff et al., 2023): The largest RCT on testosterone and cardiovascular safety (n=5,246; men aged 45-80 with hypogonadism and cardiovascular risk factors or established CVD) demonstrated non-inferiority of testosterone (1.62% gel) vs placebo for the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke): HR 0.96 (95% CI: 0.78-1.17) over a mean 33-month follow-up. While TRAVERSE used transdermal testosterone rather than injectable TU, the FDA has applied these findings across testosterone formulations, removing the cardiovascular risk warning from the Aveed label in July 2025 [8].

TU Meta-Analysis (Corona et al., 2014): A meta-analysis of injectable TU studies found significant associations with fat mass reduction and HbA1c improvement in both controlled and uncontrolled trials, particularly in hypogonadal subjects. Erectile function improvement was also observed. Blood pressure, lipid profile, waist circumference, and BMI improvements were observed in uncontrolled studies but not consistently confirmed in placebo-controlled trials [9].

POME and Anaphylaxis Data: In clinical trials, POME events were observed in 2 of 130 patients (1.5%) and anaphylaxis in 1 patient. Postmarketing data from Middleton et al. (2015) reported POME-like symptoms (primarily cough) in 2.3% of 3,022 injections in 347 men, with most events being mild and self-resolving [10].

Jockenhovel et al. (2009): Compared long-acting TU to testosterone enanthate in hypogonadal men. Both treatments improved sexual function and mood, with TU providing more stable serum testosterone levels and fewer peak-trough fluctuations [11].

Evidence & Effectiveness Matrix

Benefits & Therapeutic Effects

The Basics

The primary benefit of testosterone undecanoate injectable is restoring testosterone to the normal range in men with diagnosed hypogonadism, which can improve a constellation of symptoms affecting daily life. For many men, this means improvement in energy levels, sexual function, mood stability, and body composition over time.

What sets TU apart from other injectable testosterone formulations is the convenience of infrequent injections. Instead of injecting every one to two weeks with cypionate or enanthate, TU requires roughly five to six injections per year. For men who dislike needles, travel frequently, or simply want less treatment burden, this represents a meaningful quality-of-life improvement. Long-term Nebido users frequently describe the freedom of "only having to think about it a few times a year."

The clinical evidence from long-term TU studies shows sustained improvements in several areas: reduction in fat mass, increase in lean body mass, improvements in glycemic control (HbA1c reduction), and sustained improvements in sexual function and mood. These benefits appear to be maintained over years of treatment, with registry data spanning more than eight years showing no attenuation of effect.

The Science

Sexual function: Jockenhovel et al. demonstrated improvement in sexual function and mood scores with injectable TU comparable to testosterone enanthate, with TU providing more stable hormonal levels [11]. The TTrials Sexual Function Trial showed significant improvement in sexual desire and erectile function with testosterone therapy, though this study used transdermal testosterone [12].

Body composition: The Corona et al. (2014) meta-analysis of injectable TU studies found statistically significant reductions in fat mass and improvements in lean body mass in hypogonadal men. The long-term registry data (Saad et al.) showed progressive weight loss (average 15-20 kg over 5 years) and waist circumference reduction in obese hypogonadal men treated with TU [7][9].

Metabolic parameters: Injectable TU has demonstrated HbA1c reduction in both controlled and uncontrolled trials. Long-term data suggests sustained improvements in insulin sensitivity and metabolic syndrome parameters, particularly in obese hypogonadal men with type 2 diabetes [9].

Bone density: Long-term TU studies report improvement in bone mineral density, consistent with the known effects of testosterone and its aromatization product estradiol on osteoblast regulation and bone metabolism [7].

Risks, Side Effects & Safety

The Basics

Every TRT formulation carries risks, and testosterone undecanoate has some that are shared with all testosterone products and some that are unique to this formulation. Understanding these risks in context is important for making informed decisions with your healthcare provider.

The most common side effects are familiar to anyone on TRT: acne, injection site discomfort, and increases in hematocrit (red blood cell concentration). What makes TU different is the risk of pulmonary oil microembolism (POME), a reaction where tiny oil droplets from the large-volume injection enter the bloodstream and reach the lungs. Symptoms include sudden coughing, chest tightness, dizziness, and sweating. In clinical trials, this occurred in about 1.5% of patients, and most events resolved within 30 minutes. This is why Aveed carries a boxed warning and requires a 30-minute observation period after every injection.

Regarding heart health, the TRAVERSE trial (the largest cardiovascular safety study of testosterone therapy) found no increased risk of heart attack, stroke, or cardiovascular death with testosterone therapy compared to placebo. This led the FDA to remove the cardiovascular risk warning from the Aveed label in July 2025.

Hematocrit monitoring is essential on any form of TRT. When hematocrit rises above 54%, intervention is needed, which may include dose reduction, longer injection intervals, therapeutic phlebotomy (blood donation), or switching to a different formulation. Injectable testosterone tends to increase hematocrit more than transdermal formulations.

The Science

Common adverse reactions (clinical trial data, incidence >= 1.5%):

• Acne: 2.3%
• Injection site pain: 2.3%
• PSA increase: 2.3%
• Hypertension: 2.3%
• Hemoglobin/hematocrit increase: 1.5%
• Headache: 1.5%
• Diarrhea: 1.5%
• Vomiting: 1.5%

Pulmonary Oil Microembolism (POME):
POME is a unique risk of large-volume, oil-based intramuscular injections. In the pivotal clinical trial, POME occurred in 2 of 130 patients (1.5%). Postmarketing surveillance (Middleton et al., 2015; 3,022 injections in 347 men) reported cough or respiratory symptoms in 2.3% of injections, with the vast majority being mild and self-resolving within minutes. No life-threatening POME events were reported in this retrospective series [10]. The mechanism involves inadvertent intravascular injection or vascular disruption during the injection process, allowing oil droplets to enter the pulmonary vasculature.

Anaphylaxis:
Anaphylaxis was reported in 1 patient in clinical trials. Can occur after any injection, including the first. This risk, combined with POME, necessitates the REMS program and 30-minute post-injection observation requirement [1].

Cardiovascular safety:
The TRAVERSE trial (n=5,246; men aged 45-80 with hypogonadism and cardiovascular risk factors) demonstrated non-inferiority of testosterone vs placebo for the primary MACE composite endpoint: HR 0.96 (95% CI: 0.78-1.17) over 33 months. In absolute terms, this translates to no additional major cardiovascular events per 1,000 patient-years attributable to testosterone therapy. TRAVERSE also noted increased incidence of atrial fibrillation (HR 1.26), pulmonary embolism, and acute kidney injury in the testosterone group, warranting continued monitoring [8]. The FDA removed the cardiovascular risk warning from the Aveed label in July 2025 following review of TRAVERSE data.

Polycythemia/erythrocytosis:
Testosterone stimulates erythropoiesis via erythropoietin (EPO) induction and direct effects on erythroid progenitor cells. Hematocrit >54% is the threshold for clinical intervention (dose reduction, therapeutic phlebotomy, route change). Injection-based testosterone tends to increase hematocrit more than transdermal formulations due to higher peak levels, though TU's more gradual absorption may partially mitigate this effect compared to cypionate/enanthate [1][8].

Prostate considerations:
PSA increase was reported in 2.3% of clinical trial patients. Current evidence based on the saturation model does not support a causal link between TRT at physiological testosterone levels and prostate cancer initiation. However, PSA monitoring and digital rectal examination (per age-appropriate guidelines) remain standard practice during TRT [1].

Venous thromboembolism (VTE):
Postmarketing reports include DVT and PE. The July 2025 label update addressed VTE risk language. Patients with thrombophilia or prior VTE history should be monitored closely [1].

Hepatotoxicity:
Unlike 17-alpha-alkylated oral androgens, injectable testosterone undecanoate is not associated with hepatotoxicity, peliosis hepatis, or hepatic neoplasms [1].

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're noticing acne, water retention, mood changes, or any other shift, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Testosterone undecanoate injectable follows a different dosing rhythm than other injectable testosterone products. Instead of weekly or biweekly injections, TU uses a loading phase followed by maintenance injections every 10 to 14 weeks.

With Aveed (US), the protocol is: a first injection at the start, a second injection four weeks later, and then one injection every ten weeks from that point forward. With Nebido (international), the protocol is similar but starts with the second injection at six weeks, followed by injections every 10 to 14 weeks, typically every 12 weeks.

The loading phase is important. Those first two closely spaced injections build up the depot in the muscle tissue that sustains levels over the longer interval. Without the loading phase, it would take several months before blood levels reached a therapeutic range.

One important point: the injection interval is not one-size-fits-all. Some men metabolize TU faster than others, and their testosterone levels may drop below the target range before the next scheduled injection. Trough blood levels (drawn just before the next injection is due) are the best way to determine whether the interval needs to be shortened. Some providers prescribe TU at intervals of 6-8 weeks based on individual trough levels, though this is off-label for the Aveed formulation.

Each injection is a significant volume (3 mL for Aveed, 4 mL for Nebido) and must be injected deep into the gluteal muscle over 60-90 seconds. This is not a quick self-injection; it requires a healthcare professional in the US due to the REMS program.

The Science

FDA-approved dosing (Aveed):

• Loading: 750 mg (3 mL) IM at week 0 and week 4
• Maintenance: 750 mg (3 mL) IM every 10 weeks thereafter
• Injection site: Deep gluteal (dorsogluteal) muscle only
• Injection speed: Slowly over 60-90 seconds
• Needle: 21-gauge, 1.5-inch
• Post-injection observation: 30 minutes (REMS requirement)

International dosing (Nebido):

• Loading: 1000 mg (4 mL) IM at week 0 and week 6
• Maintenance: 1000 mg (4 mL) IM every 10-14 weeks (typically every 12 weeks)
• First interval adjustment recommended after trough level measurement at 12 weeks

Dose adjustment considerations:

• Trough testosterone levels should be measured before the third injection (earliest opportunity for steady-state assessment)
• Target trough: 300-500 ng/dL (varies by clinician preference and patient symptoms)
• If trough is below target: Shorten the injection interval by 2-4 weeks
• If trough is above target or adverse effects develop: Extend the interval
• Dose per injection is fixed (750 mg Aveed / 1000 mg Nebido); adjustment is made by changing the interval, not the dose

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually injecting, including doses, frequency, and any adjustments, makes that process smoother. Doserly tracks your testosterone doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you drew up the right amount or when your last injection was. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes testosterone therapy most effective and keeps your levels stable between injections.

What to Expect (Timeline)

Days 1-7: The injection itself takes 60-90 seconds and may cause temporary soreness at the injection site. Some men experience a POME reaction (coughing, chest tightness, dizziness) during or immediately after injection, which typically resolves within 30 minutes. The 30-minute observation period at the clinic is mandatory for Aveed. Testosterone levels begin rising as the depot releases TU.

Weeks 2-4: Peak testosterone levels are typically reached within 7-14 days. During this window, some men notice improved energy, libido, and mood. This is when the second loading dose is given (Aveed at week 4, Nebido at week 6).

Months 1-3: After the loading phase, testosterone levels should be stabilizing within the normal range. Early benefits may include improved energy, initial libido changes, and mood stabilization. Hematocrit begins to rise and should be checked at the first follow-up blood draw (4-12 weeks). Acne may develop in some patients.

Months 3-6: Sexual function improvements become more consistent. Body composition changes begin (reduction in fat mass, gradual increase in lean mass). Bone density changes are beginning but not yet measurable. Monitoring should include trough testosterone levels before the next injection to assess whether the interval is appropriate.

Months 6-12: Full steady state is achieved. Body composition changes become more pronounced. Sexual function benefits are well-established. Annual monitoring protocol begins (hematocrit, PSA, lipids, testosterone levels). Some men may notice that the standard interval is too long and may need interval adjustment.

Ongoing maintenance: Annual review with provider including symptom assessment, blood work review, and risk-benefit discussion. Continued hematocrit monitoring every 6-12 months. PSA monitoring per age-appropriate guidelines. Reassess need for TRT periodically.

Realistic expectations: Not every symptom improves at the same rate, and some may not fully resolve with TRT alone. Individual response varies significantly. The loading phase may feel frustrating as levels build slowly. Patience and consistent follow-up with your provider are essential.

Fertility Preservation & HPG Axis

Exogenous testosterone, regardless of formulation, suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback on GnRH pulse frequency and amplitude. This suppression reduces LH and FSH secretion, leading to a dramatic decline in intratesticular testosterone concentrations (normally 40-100 times higher than serum levels) and subsequent impairment of Sertoli cell function and spermatogenesis [6].

Testosterone undecanoate has been specifically studied as a male contraceptive agent, which underscores the potency of its spermatogenesis-suppressing effects. Zhang et al. (1998) studied injectable TU (1000 mg) as a potential male contraceptive, demonstrating effective suppression of sperm counts to azoospermia or severe oligospermia in the majority of subjects [13].

Timeline of suppression: Sperm count decline typically begins within 2-3 months of TRT initiation. Approximately 40-60% of men on TRT achieve azoospermia by 6 months, with the remainder typically showing severe oligospermia (<1 million/mL) [6].

Fertility preservation options:

• HCG co-administration: 250-500 IU 2-3 times weekly to maintain intratesticular testosterone and support ongoing spermatogenesis. Not universally recommended, and evidence for its efficacy during long-term TRT is limited.
• Clomiphene/enclomiphene: SERMs that can raise endogenous T by stimulating LH/FSH without suppressing spermatogenesis. Used as alternatives to exogenous T for men prioritizing fertility. Off-label for this indication.
• Sperm banking: Recommended before TRT initiation for any man who may want biological children in the future.

Recovery after discontinuation: Variable timeline of 6-24+ months. Recovery is not guaranteed. Factors affecting recovery include duration of TRT use, age, pre-TRT hormonal status, whether HCG was used concurrently, and individual genetic factors. Men with primary hypogonadism (testicular failure) have limited recovery potential regardless of intervention. Men with secondary hypogonadism generally have a better prognosis for HPG axis recovery.

Clinical importance: Fertility counseling should be part of every TRT initiation conversation for men of reproductive age. This is not a minor or reversible side effect; it requires proactive planning.

Interactions & Compatibility

Drug-drug interactions:

• Anticoagulants (warfarin, DOACs): Testosterone may enhance anticoagulant effect. Frequent INR monitoring recommended when initiating or adjusting TRT. See your prescriber for dose adjustments.
• Insulin and diabetes medications: Testosterone may improve insulin sensitivity and decrease blood glucose. Diabetes medication doses may need adjustment. Monitor blood glucose closely during TRT initiation.
• Corticosteroids: Concurrent use may enhance fluid retention and edema.
• 5-alpha reductase inhibitors (finasteride, dutasteride): Blocks conversion of testosterone to DHT. May reduce androgenic side effects (hair loss, prostate stimulation) but also reduces some beneficial effects. See Estrogen Management on TRT for related discussion.
• Aromatase inhibitors (anastrozole): Sometimes co-prescribed for estrogen management. See Section Section 18 and Estrogen Management on TRT.
• Opioids: Chronic opioid use suppresses the HPG axis and may be an underlying cause of hypogonadism. If opioid-induced, addressing the opioid use may reduce or eliminate the need for TRT.

Supplement interactions:

• DHEA: Additive androgenic effects. Use with caution and monitor.
• Boron: May increase free testosterone by reducing SHBG.
• Zinc: Supports testosterone production; important to avoid deficiency but supplementation above RDA has limited evidence for boosting levels.
• Saw palmetto: 5-alpha reductase inhibiting properties.
• Vitamin D: Associated with testosterone levels; important to correct deficiency.

Lifestyle factors:

• Alcohol: Suppresses T production and increases aromatization. Minimize consumption during TRT.
• Sleep: Critical for hormonal function. TRT may worsen sleep apnea; discuss with provider.
• Exercise: Resistance training is synergistic with TRT for body composition and strength benefits.
• Body composition: Weight loss in obese men may normalize testosterone, potentially reducing or eliminating the need for TRT.

Decision-Making Framework

When considering testosterone undecanoate injectable specifically, the decision involves not only whether TRT is appropriate but also whether this particular formulation is the best fit.

When TU may be a good choice:

• You prefer fewer injections per year (4-6 vs 26-52 with cypionate/enanthate)
• You have difficulty maintaining a self-injection schedule
• You travel frequently and want minimal treatment burden
• You are comfortable with office-based injections
• Your insurance covers Aveed or you have access to Nebido internationally

When TU may not be ideal:

• You prefer to self-inject at home (Aveed requires office-based administration in the US)
• Cost is a primary concern (Aveed is significantly more expensive than generic cypionate/enanthate)
• You are sensitive to peak-trough fluctuations and want the most stable levels possible (more frequent injections with shorter esters may provide flatter curves)
• You have a history of respiratory conditions that increase POME risk concern

Diagnostic criteria for TRT initiation remain the same regardless of formulation. The Endocrine Society requires two morning total testosterone measurements below the lower limit of normal (typically <264-300 ng/dL, depending on the laboratory reference range) plus symptoms of hypogonadism. The AUA uses a threshold of 300 ng/dL. Reversible causes (obesity, sleep apnea, opioid use, pituitary pathology) should be investigated before starting any TRT.

Questions to ask your provider about TU:

• How will my injection interval be individualized based on my trough levels?
• What happens if I experience a POME reaction?
• Is there a shorter-ester fallback if TU doesn't work for me?
• What is the expected cost, and does my insurance cover it?
• Can I split the dose into more frequent injections if my levels drop before the interval is up?

Finding a qualified provider: Endocrinologist, urologist with andrology expertise, or men's health specialist. The REMS requirement means not every healthcare setting can administer Aveed; verify your provider is REMS-certified.

Administration & Practical Guide

Injection technique (office-administered):

• TU is administered as a deep intramuscular injection into the gluteal muscle (dorsogluteal site)
• A 21-gauge, 1.5-inch needle is used
• The injection volume is large: 3 mL (Aveed) or 4 mL (Nebido)
• Injection speed: Slowly over 60-90 seconds to minimize pain and reduce POME risk
• The vial should be warmed and shaken for about 5 seconds before use to ensure the solution is liquid
• Patient position: Standing and leaning forward on a surface, or lying prone

Post-injection requirements (US/REMS):

• Remain in the healthcare setting for 30 minutes after injection
• Report any symptoms of POME (coughing, chest tightness, dizziness, sweating, throat tightening) immediately
• You should not drive if you experience POME symptoms

Injection site management:

• Some soreness at the injection site is normal and may last 1-3 days
• Walking after the injection can help disperse the oil and reduce soreness
• Ice packs may help with injection site discomfort
• Do not massage the injection site vigorously

Self-injection (Nebido, international):
Some countries permit self-injection of Nebido after appropriate training, though the large volume and gluteal injection site make self-administration more challenging than with smaller-volume cypionate or enanthate injections. Some patients who split Nebido into smaller, more frequent doses (off-label) find self-injection more practical.

Storage:

• Store at controlled room temperature: 25 degrees C (77 degrees F)
• Excursions permitted to 15-30 degrees C (59-86 degrees F)
• Single-use vial (do not save partially used vials)

Monitoring & Lab Work

Pre-TRT baseline labs:

• Total testosterone (two morning draws, fasting preferred)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Estradiol
• SHBG
• Prolactin (if secondary hypogonadism suspected)
• Complete blood count with hematocrit
• PSA (age-appropriate, typically for men >40)
• Comprehensive metabolic panel
• Lipid panel
• DEXA scan if osteoporosis risk is indicated

Initial follow-up (after loading phase, before 3rd injection):

• Trough testosterone level (drawn just before the next scheduled injection)
• Hematocrit
• Symptom assessment
• Side effect evaluation
• Consider interval adjustment based on trough level

Ongoing monitoring:

• Hematocrit: Every 6-12 months. Threshold for intervention: >54%. Options include dose reduction, interval extension, therapeutic phlebotomy (blood donation), or route change to transdermal.
• PSA: Per age-appropriate screening guidelines. Annually for men >40.
• Testosterone levels: Trough levels before each injection during the first year, then annually or when symptoms change.
• Estradiol: Only if symptomatic (gynecomastia, fluid retention, mood changes). Not routine per clinical guidelines.
• Lipid panel: Annually.
• Bone density (DEXA): If osteoporosis was an indication, repeat per clinical protocol.
• Semen analysis: If fertility is a concern.

Annual review checklist: Symptom reassessment, continued indication for TRT, risk-benefit discussion, dose/interval optimization, vaccination and health screening updates.

Estrogen Management on TRT

Testosterone aromatizes to estradiol via the aromatase enzyme, primarily in adipose tissue. This is a normal and necessary physiological process. Estradiol plays important roles in bone health, cardiovascular function, libido, and cognitive function in men.

When estrogen management matters with TU: The long-acting nature of TU means that peak testosterone levels (and consequently peak E2 levels) occur during the first 1-2 weeks post-injection, followed by a gradual decline. Clinical trial data shows that the E2:T ratio remains within the reference range at steady state, suggesting that aromatization patterns with TU are physiologically appropriate for most patients [2].

Aromatase inhibitor (AI) use: The Endocrine Society and AUA do not recommend routine AI co-prescription with TRT. AI use should be reserved for clinical symptoms of elevated estradiol (gynecomastia, significant fluid retention) that persist despite dose or protocol optimization. When used, anastrozole is typically prescribed at 0.25-0.5 mg 2-3 times weekly, titrated to symptom response.

Why NOT to use an AI routinely: Excessive estradiol suppression causes joint pain, mood disturbance, decreased libido (paradoxically), and bone density loss. Low E2 symptoms can be more debilitating than elevated E2 symptoms. The community emphasis on "dialing in" E2 to a specific number (often 20-35 pg/mL on the sensitive assay) is not supported by clinical guidelines, which recommend symptom-based management.

Target E2 ranges:

• Clinical guidelines: No specific target range for men on TRT. Treat symptoms, not numbers.
• Men's health community: Often targets 20-35 pg/mL. Not evidence-based but widely discussed.
• Balanced perspective: E2 should be proportionate to total T. Symptomatic management is preferred over number chasing.

Stopping TRT / Post-Cycle Considerations

HPG axis recovery after TU discontinuation: When exogenous testosterone is discontinued, LH and FSH remain suppressed for weeks to months as the depot slowly clears. The very long half-life of TU (~34 days) means that testosterone levels decline more gradually than with shorter esters, which may slightly delay the start of HPG axis recovery.

PCT protocols (community-derived, limited formal evidence):

• HCG taper: 1000-2000 IU every other day for 2-4 weeks, then taper. May be started before the last TU injection to support testicular function during the transition.
• Clomiphene citrate: 25-50 mg daily for 4-8 weeks to stimulate LH/FSH recovery
• Enclomiphene: Newer SERM, may have fewer side effects than clomiphene
• Note: PCT protocols are not standardized in clinical guidelines for TRT discontinuation. These are community practices with limited formal study.

Is TRT lifelong? For men with primary hypogonadism (testicular failure), TRT is typically lifelong because the underlying cause cannot be reversed. For secondary hypogonadism, addressing underlying causes (weight loss, sleep apnea treatment, opioid cessation) may restore endogenous production. For age-related decline, the answer is individualized.

Recovery expectations: Variable timeline of 6-24+ months. Not guaranteed. Duration of TRT use, age, pre-TRT hormonal status, and concurrent HCG use all affect recovery. Symptoms of hypogonadism will likely return during the recovery period.

Special Populations & Situations

Obese Men

Weight loss alone may normalize testosterone in obese men with hypogonadism. Consider lifestyle intervention first. If TRT is initiated, higher aromatization in adipose tissue may produce more estradiol. The long-term TU registry data shows significant weight loss and metabolic improvement in obese hypogonadal men on TU, suggesting a potential therapeutic benefit [7].

Men with Sleep Apnea

TRT may exacerbate obstructive sleep apnea. CPAP optimization before and during TRT is recommended. Sleep study before TRT initiation is advisable in men with risk factors. The label notes this as a warning.

Men with Prostate Cancer History

Historically an absolute contraindication. Evidence is evolving. The saturation model suggests that exogenous testosterone may not further stimulate the prostate at physiological replacement levels. Active surveillance patients are being studied. Requires specialized urological consultation.

Cardiovascular Disease History

The TRAVERSE trial provides reassurance that testosterone therapy does not increase major cardiovascular events in high-risk men. Hematocrit monitoring is critical. Transdermal formulations may be preferred for hematocrit management in very high-risk patients.

Type 2 Diabetes

TU has demonstrated improvements in insulin sensitivity, HbA1c, and metabolic parameters in hypogonadal diabetic men. Diabetes medication doses may need adjustment. The metabolic benefits of TU are particularly well-documented in the long-term registry data [7][9].

Adolescents and Young Men

Safety and efficacy of Aveed not established in males under 18. Constitutional delay of puberty must be distinguished from true hypogonadism. Fertility implications are especially critical in this population.

Transgender Men (FTM)

Nebido/Reandron is commonly used in FTM hormone therapy internationally due to the convenience of infrequent injections. Community satisfaction is generally high. Dosing goals differ from TRT (masculinizing levels). Fertility counseling (oocyte preservation) is essential before initiation.

Older Men (>65)

Age-related decline vs true hypogonadism debate applies. TRAVERSE and TTrials data primarily from this population. Lower starting doses or longer intervals may be appropriate. Increased polycythemia risk with age. Prostate monitoring is heightened.

Regulatory, Insurance & International

United States (FDA/DEA):

• DEA Schedule III classification
• REMS program required: certified providers and healthcare settings only
• FDA-approved for primary and hypogonadotropic hypogonadism only; "age-related hypogonadism" explicitly NOT an approved indication
• July 2025: Cardiovascular risk warning removed from label
• NDA 022219 (original approval March 2014)
• Insurance coverage: Prior authorization often required. Cost approximately $2,130 per injection ($710/mL). Significantly more expensive than generic testosterone cypionate ($20-50 per vial).
• Not available from compounding pharmacies; brand name only

United Kingdom (MHRA):

• Available as Nebido (1000 mg/4 mL)
• NHS prescribing available through endocrinology or urology referral
• Private TRT clinics also prescribe Nebido
• No REMS equivalent; may be self-administered after training

Canada:

• Nebido is not currently approved by Health Canada
• Testosterone cypionate and enanthate are the primary injectable options

Australia (TGA):

• Available as Reandron 1000 (bioequivalent to Nebido)
• PBS listed for approved indications
• Self-injection permitted after training

European Union (EMA):

• Nebido is widely available across EU member states
• EAU guidelines include TU as a first-line injectable option
• No REMS equivalent; many countries allow self-administration

Travel considerations:

• Carrying controlled substances internationally requires documentation (prescription letter from provider, original packaging)
• The long injection interval of TU is advantageous for travelers, as they may not need to carry supplies for extended trips
• Verify country-specific testosterone laws before traveling

Frequently Asked Questions

What is the difference between Aveed and Nebido?
Both contain testosterone undecanoate in castor oil. Aveed (US) is 750 mg/3 mL given every 10 weeks after loading. Nebido (international) is 1000 mg/4 mL given every 10-14 weeks after loading. Aveed requires a REMS program with 30-minute post-injection observation; Nebido generally does not have this restriction. Nebido is typically less expensive.

Can I self-inject testosterone undecanoate?
In the US, Aveed must be administered in a certified healthcare setting due to the REMS program. In many other countries, self-injection of Nebido is permitted after appropriate training, though the large injection volume (4 mL) and gluteal injection site make it more challenging than self-injecting cypionate or enanthate.

Why does Aveed have a boxed warning?
Because of the risk of pulmonary oil microembolism (POME) and anaphylaxis, which can occur after any injection. The 30-minute observation period allows healthcare providers to respond if these reactions occur.

What if my testosterone levels crash before my next injection?
This is a common concern. If trough levels drop below the therapeutic range, your provider can shorten the injection interval. Some clinicians use 6-8 week intervals instead of the standard 10 weeks. Trough blood work (drawn just before the next injection) is the key to finding the right interval.

Is testosterone undecanoate more effective than cypionate or enanthate?
All testosterone esters produce the same free testosterone once the ester is cleaved. The difference is in pharmacokinetics (how quickly levels rise and fall) and convenience (injection frequency). TU is not more or less effective; it is a different delivery profile.

How much does Aveed cost?
In the US, approximately $2,130 per injection (about $710 per mL). With approximately 5-6 injections per year, the annual cost is roughly $10,000-$13,000 before insurance. Generic testosterone cypionate costs approximately $20-50 per vial. Insurance coverage varies; prior authorization is often required.

What does a POME reaction feel like?
Symptoms include sudden urge to cough, shortness of breath, throat tightening, chest pain, dizziness, and sweating. Most events resolve within 30 minutes. If you experience these symptoms during or after injection, inform your healthcare provider immediately.

Can I switch from cypionate/enanthate to testosterone undecanoate?
Yes, with your provider's guidance. The transition is typically straightforward: your last short-ester injection is replaced by the first TU injection. Your provider will monitor trough levels to ensure adequate coverage during the transition.

Does testosterone undecanoate cause fewer side effects?
The side effect profile is similar to other testosterone formulations, with the exception of the POME/anaphylaxis risk unique to TU. Some data suggests slightly more stable hormone levels may reduce fluctuation-related side effects (mood swings, energy dips), but this depends on individual pharmacokinetics and whether the injection interval is optimized.

Why is Nebido not available in the US?
Nebido is not FDA-approved in the US. Aveed is the US-approved version of injectable TU. The formulations are similar but differ in dose (750 mg vs 1000 mg) and some inactive ingredients. The Nebido manufacturer (Bayer) has not pursued separate FDA approval for the Nebido formulation.

Myth vs. Fact

Myth: "You only need 4-5 injections per year with testosterone undecanoate."
Fact: While the approved Aveed protocol calls for injections every 10 weeks (approximately 5 per year), many patients require more frequent injections to maintain therapeutic levels throughout the interval. Trough-level testing is essential to determine the optimal frequency for each individual. The interval should be personalized, not assumed to work for everyone at the standard 10-week mark.

Myth: "TRT causes heart attacks."
Fact: The TRAVERSE trial (n=5,246, the largest cardiovascular safety RCT for testosterone therapy) found no increased risk of major cardiovascular events with testosterone vs placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months in men with cardiovascular risk factors. The FDA removed the cardiovascular risk warning from the Aveed label in July 2025 based on this evidence [8].

Myth: "TRT causes prostate cancer."
Fact: Current evidence based on the androgen receptor saturation model does not support a causal relationship between TRT at physiological replacement levels and prostate cancer initiation. PSA monitoring remains standard practice, and men with active or untreated prostate cancer should not receive TRT. The relationship between testosterone and prostate tissue is more nuanced than the historical assumption [1].

Myth: "Once you start TRT, you can never stop."
Fact: Whether TRT is lifelong depends on the underlying cause. Men with primary testicular failure typically require lifelong replacement. Men with secondary hypogonadism may recover endogenous production if underlying causes (obesity, sleep apnea, opioid use) are addressed. Recovery after TRT discontinuation is possible but not guaranteed, and may take 6-24+ months.

Myth: "TRT will make you permanently infertile."
Fact: TRT suppresses spermatogenesis, and testosterone undecanoate has been specifically studied as a male contraceptive agent. However, fertility is usually recoverable after TRT discontinuation, though recovery timelines are variable (6-24+ months) and not guaranteed. Sperm banking before TRT initiation is recommended for men who may want biological children [6][13].

Myth: "Aveed is safer than self-injecting testosterone at home."
Fact: Aveed has a unique POME and anaphylaxis risk that home-injected cypionate and enanthate do not carry. The REMS requirements exist specifically because of these risks, not because Aveed is inherently safer in other respects. The side effect profile beyond POME/anaphylaxis is similar to other injectable testosterone formulations.

Myth: "All men over 40 need TRT."
Fact: Age-related testosterone decline is a normal physiological process, not a disease. Only men with confirmed hypogonadism (two morning total T measurements below the lower limit of normal plus symptoms) are candidates for TRT. Lifestyle factors (weight management, sleep optimization, exercise) should be addressed first. The FDA explicitly notes that safety and efficacy of Aveed in men with "age-related hypogonadism" have not been established [1].

Myth: "Higher testosterone doses are always better."
Fact: Therapeutic replacement aims to restore testosterone to the normal physiological range (typically 300-1000 ng/dL). Supraphysiological levels increase the risk of polycythemia, cardiovascular complications, sleep apnea exacerbation, and other adverse effects without proportionally greater benefit for most outcomes.

Sources & References

Clinical Guidelines

1. Aveed (testosterone undecanoate) injection. Full Prescribing Information. Endo USA, Inc. Revised July 2025. NDA 022219. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045
2. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31(5):457-465. doi:10.2164/jandrol.109.009597
3. U.S. Food and Drug Administration. Aveed NDA 022219 approval letter. March 5, 2014.

Landmark Trials

1. Partsch CJ, Weinbauer GF, Fang R, Nieschlag E. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol. 1995;132(4):514-519.
2. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8(1):1-28.
3. Patel AS, Leong JY, Ramasamy R. Prediction of male infertility by the World Health Organization laboratory manual for assessment of semen analysis: A systematic review. Arab J Urol. 2018;16(1):96-102.

Systematic Reviews & Meta-Analyses

1. Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl. 2007;9(3):291-297.
2. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025
3. Corona G, Giagulli VA, Maseroli E, et al. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15(13):1903-1926.

Observational Studies

1. Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol. 2015;172(5):511-517.
2. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol. 2009;160(5):815-819.
3. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. (TTrials)
4. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 1999;84(10):3642-3647.

Government/Institutional Sources

1. U.S. Drug Enforcement Administration. Controlled Substances Schedule III. Testosterone.
2. Campbell K, Muthigi A, Ghomeshi A, et al. Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights. Drug Healthc Patient Saf. 2023;15:73-84. doi:10.2147/DHPS.S383130

Related Guides & Cross-Links

Same Category (Injectable Testosterone)

• Testosterone Cypionate (Depo-Testosterone)
• Testosterone Enanthate (Delatestryl)
• Testosterone Propionate
• Testosterone Cypionate Auto-Injector (Azmiro)
• Testosterone Enanthate Auto-Injector (Xyosted)
• Sustanon 250

Related Treatment Options

• Testosterone Injections Guide
• Testosterone Gels & Topicals Guide
• Oral Testosterone Guide
• TRT for Beginners

Ancillary Medications

• Human Chorionic Gonadotropin (HCG)
• Anastrozole (Arimidex)
• Clomiphene Citrate (Clomid)
• Enclomiphene Citrate

Fertility & HPG Axis

• Fertility Preservation on TRT
• Stopping TRT & Post-Cycle Recovery

Conditions

• Primary Hypogonadism
• Secondary Hypogonadism
• Late-Onset Hypogonadism

Educational

• The TRAVERSE Trial Explained
• TRT Myths vs Facts
• TRT Blood Work Guide